Nano Dimension Appoints Independent Director; Epigenetics Term Sheet Expires

What Happened
Nano Dimension Ltd. filed an 8‑K on August 18, 2026 announcing two items: the board appointed Nadav Kidron as a Class II independent director effective August 16, 2026, and the 30‑day exclusivity period under a non‑binding term sheet with Infinite Epigenetics, Inc. expired on July 15, 2026 with no definitive agreement reached as of the filing.

Key Details

• Nadav Kidron appointed to the Board effective August 16, 2026 as a Class II director; term expires at the Company’s 2026 annual meeting.
• The Board determined Mr. Kidron is independent under Nasdaq rules; he will serve on the Audit Committee and Compensation Committee.
• Mr. Kidron is President, CEO and director of Oramed Pharmaceuticals since March 2006 and Chairman of its board since June 2022; he holds an LLB and International MBA from Bar‑Ilan University.
• The 30‑day exclusivity period for the non‑binding term sheet with Infinite Epigenetics expired on July 15, 2026; no definitive agreement was reached as of the 8‑K filing.

Why It Matters
An independent director appointment—especially one joining the Audit and Compensation Committees—can affect corporate governance and oversight, which investors often watch for board independence and financial oversight. Separately, the expiration of the exclusivity period on the Infinite Epigenetics term sheet means there is no signed deal in place as of the filing date, so any potential strategic transaction with that party is not imminent.